Fencl-2007

Clinical settingPatients with suspected malignancy and unidentified primary, referred for PET/CT at a single institution. Initial tests (diagnostic imaging, medical history, clinical examination and lab tests) had not revealed a primary tumour.
Participants and Country190 patients with Czech Republic.
Study designRetrospective case series.
Target conditionIdentification of the primary tumour site. Reference standard was the histology of the primary tumour and/or clinical/radiological follow up.
TestsFDG PET/CT, Siemnens Biograph Duo LSO PET/CT. 350 to 450 MBq FDG.
Follow up
Study Type
PET imaging field
Biopsy of metastasis82/190 (43%) had histologically proved metastases: poorly differentiated carcinoma (35/82, 43%), adenocarcinoma (24/82, 29%), squamous cell carcinoma (5/82, 6%), mucinous carcinoma (10/82, 12%), spinocellular carcinoma (7/82, 9%) and 1 small cell carcinoma. 108/190 (57%) there was only clinical suspicion of malignancy.
Notes

From: Guideline chapter 2, Diagnosis

Cover of Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin
Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin.
NICE Clinical Guidelines, No. 104.
National Collaborating Centre for Cancer (UK).
Copyright © 2010, National Collaborating Centre for Cancer.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licenses issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.